Data from these results indicate that the CCL20/CCR6 axis is implicated in the pathogenesis of autoimmune diseases and that antibodies or antagonists to CCR6 or CCL20 hold promise as an intriguing treatment tactic to ameliorate neuroinflammation and autoimmunity. The gene discussed is CCR6; the disease is autoimmune disease.